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Background: Treatment with maximal dosages of atorvastatin and rosuvastatin produces marked regression of coronary atherosclerosis. The 
relative impact of different lipid and lipoprotein levels on changes in atheroma burden are unknown.
Methods: 1039 patients with coronary artery disease underwent serial imaging with intravascular ultrasound to evaluate the effect of treatment 
with atorvastatin 80 mg or rosuvastatin 40 mg for 24 months. The association between achieved levels of lipids and lipoproteins with changes in 
total atheroma volume (TAV) were investigated.
Results: Rosuvastatin-treated patients demonstrated lower levels of LDL-C (62 vs 70 mg/dL, p<0.0001), non-HDL-C (89 vs 95 mg/dL, p<0.0001), 
apolipoprotein B (73 vs 75 mg/dL, p=0.028) and higher levels of HDL-C (50 vs 48 mg/dL, p=0.01), and apolipoprotein A-1 (147 vs 138 mg/
dL, p<0.0001). This lipoprotein pattern associated with a greater degree of regression of TAV (-6.4 v -4.4 mm3, p=0.01). In the entire cohort 
changes in TAV directly correlated with achieved levels of LDL-C (r=0.11, p=0.0007), non-HDL-C (r=0.10, p=0.002), LDL-C/HDL-C (r=0.09, 
p=0.002), apolipoprotein B (r=0.09, p=0.004) and the apolipoprotein B/A-I ratio (r=0.07, p=0.03). Further investigation of achieved LDL-C levels 
demonstrated less than half the regression in patients in the highest quartile (LDL-C >76.7 mg/dL, change in TAV of -3.7 mm3), compared with 
subjects in the lower three quartiles (-7.7 to -8.9 mm3, p<0.001). In contrast, no association was observed between changes in TAV and HDL-C (r=-
0.01, p=0.79) or apolipoprotein A-I (r=0.02, p=0.55).
Conclusion: Achieved levels of atherogenic lipid levels associate more closely with changes in atheroma volume compared with changes in 
protective lipid variables. These findings provide mechanistic insight into the greater degree of regression observed in rosuvastatin-treated patients.
